Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are...
Q: The track theme is on the topic “How do we accelerate and deliver on the promise of cancer immunotherapy?” What are some key promises regarding immune-oncology, that we can build upon and translate into reality and how can we expedite delivery? A: The use of...
Q: You are the CEO of Genetic Alliance. What is your role as the CEO and why is this organization so important? A: I actually try to avoid formal roles as CEO; instead, I practice showing up fully for our community: our staff and all of...
Q: Israel is known as a leader in hi-tech innovation. Can you tell us about some of the breakthrough companies in digital health and precision medicine? A: The Israeli life sciences industry continues to grow and improve its global position. Israeli entrepreneurs' ability to take advantage...
AI and machine learning are poised to create a paradigm-shift in many areas of the healthcare sector. A recent Accenture report predicted that the AI/Machine Learning healthcare market could see an ELEVEN-FOLD INCREASE in value in less than a decade...
Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are...
Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are...
Q: What need is Insitro addressing? A: Despite the marvels and triumphs of modern medicine many diseases remain untreatable. And the development of novel therapeutics to address these conditions isn’t getting any easier or cheaper, with clinical trial success rates hovering in the single-digits and the...
Q: Checkpoint inhibitors, particularly with PD-L1/PD-1 targeting agents, have benefited a broad range of patients with cancer. How will we improve on this? A: It’s true that PD-L1/PD-1 inhibitors have led to durable responses in a subset of patients, and survival benefit in many of the...
Precision medicine advancements are real as demonstrated by the high volume of molecular, “precise” drugs on the market, which are based on extensive molecular and translational understanding of the specific drug targets....
